10-Q · February 6, 2026
Immunovant, Inc. reported net losses of $110.6 million for the third quarter of 2026, narrowing slightly from a loss of $111.1 million in the same period last year. The company continues to show no revenue generation…
Earnings analysis · 10-K
IMVT earnings analysis
Filed May 20, 2026 · Our reading of the company's report
The latest report
Immunovant, Inc. continues its focus on developing IMVT-1402 as a best-in-class anti-FcRn antibody, particularly following the discontinuation of batoclimab. Despite high R&D expenses leading to significant losses, the…
Read full summary
Immunovant, Inc. continues its focus on developing IMVT-1402 as a best-in-class anti-FcRn antibody, particularly following the discontinuation of batoclimab. Despite high R&D expenses leading to significant losses, the company maintains a strong cash position of $902.1 million to support its clinical trials across multiple autoimmune disease indications. However, uncertainties remain regarding the commercialization timeline and potential market risks stemming from macroeconomic pressures.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-2.77
What stood out
-
Strong Cash Position
Cash and cash equivalents stood at $902.1 million as of March 31, 2026, providing a buffer for ongoing R&D.
-
Increased R&D Focus on IMVT-1402
The company will fully focus on IMVT-1402 development after discontinuing batoclimab, reflecting a strategic shift to prioritize best-in-class treatments.
-
Diverse Clinical Pipeline
Immunovant is progressing with trials in multiple autoimmune diseases, including Graves’ disease, MG, CIDP, and Sjögren’s disease.
-
Substantial R&D Expense Increase
R&D expenses rose to $456.7 million in 2026, driven by ongoing trials for IMVT-1402, increasing by $95.7 million YOY.
-
Market Opportunity for FcRn Inhibition
Third-party estimates suggest over 4 million patients in the U.S. and Europe could benefit from anti-FcRn treatments.
-
Upcoming Phase 3 Results in 2027
Top-line results from potentially registrational trials of IMVT-1402 in Graves’ disease and myasthenia gravis are expected in 2027, which could significantly impact future valuations.
What to watch
-
Significant Net Losses
Net loss widened to $505.6 million in FY 2026 from $413.8 million the previous year, indicating ongoing financial strain.
-
Discontinuation of Batoclimab
The decision to discontinue batoclimab across all indications poses a risk to strategic diversification and revenue opportunities.
-
Market and Geopolitical Risks
Macroeconomic conditions, particularly geopolitical tensions and inflation, could adversely affect future operations and clinical trials.
Management's outlook
No explicit guidance provided for future quarters; focus remains on clinical trials and pipeline development.
Earlier filings 4
10-Q · November 10, 2025
Immunovant, Inc. continues to report no revenues for Q2 FY2026, with an increased net loss of $126.5 million compared to a loss of $109.1 million in Q2 FY2025. R&D expenses rose notably to $114.2 million, driven…
10-Q · August 11, 2025
Immunovant, Inc. reported a net loss of $120.6 million for Q1 FY2026, fueled by escalating research and development expenses, yet continues to lack revenue generation. Cash resources have decreased to $598.9 million,…
10-K · May 29, 2025
Immunovant, Inc. continues to focus on the development of its leading candidate, IMVT-1402, aimed at treating autoimmune diseases. While the company has not generated any revenue and reported significant net losses, it…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.